Business Description
Nabriva Therapeutics PLC
NAICS : 325414
SIC : 2836
ISIN : IE000OZRGNV6
Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.04 | |||||
| Equity-to-Asset | -1.54 | |||||
| Debt-to-Equity | -0.03 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 2/9 | |||||
| Beneish M-Score | -22.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -20.1 | |||||
| 3-Year EBITDA Growth Rate | 57.5 | |||||
| 3-Year EPS without NRI Growth Rate | 57.6 | |||||
| 3-Year FCF Growth Rate | 61.6 | |||||
| 3-Year Book Growth Rate | -78.9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.68 | |||||
| 9-Day RSI | 34.88 | |||||
| 14-Day RSI | 39.06 | |||||
| 6-1 Month Momentum % | -15.03 | |||||
| 12-1 Month Momentum % | -97.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.38 | |||||
| Quick Ratio | 0.38 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 143.12 | |||||
| Days Sales Outstanding | 112.72 | |||||
| Days Payable | 66.88 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -103.8 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -16.64 | |||||
| Operating Margin % | -169.17 | |||||
| Net Margin % | -187.34 | |||||
| FCF Margin % | -44.92 | |||||
| ROE % | -642.51 | |||||
| ROA % | -162.1 | |||||
| ROIC % | -482.06 | |||||
| ROC (Joel Greenblatt) % | -673.98 | |||||
| ROCE % | -570.92 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.03 | |||||
| EV-to-EBITDA | 0.03 | |||||
| EV-to-Revenue | -0.06 | |||||
| EV-to-FCF | 0.13 | |||||
| Earnings Yield (Greenblatt) % | 3333.33 | |||||
| FCF Yield % | 15.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nabriva Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 28.191 | ||
| EPS (TTM) (€) | -14.127 | ||
| Beta | 0 | ||
| Volatility % | 100.29 | ||
| 14-Day RSI | 39.06 | ||
| 14-Day ATR (€) | 0.039165 | ||
| 20-Day SMA (€) | 1.3435 | ||
| 12-1 Month Momentum % | -97.52 | ||
| 52-Week Range (€) | 1.14 - 52.325 | ||
| Shares Outstanding (Mil) | 3.2 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nabriva Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nabriva Therapeutics PLC Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nabriva Therapeutics PLC Frequently Asked Questions
What is Nabriva Therapeutics PLC(STU:NTY)'s stock price today?
The current price of STU:NTY is €1.25. The 52 week high of STU:NTY is €52.33 and 52 week low is €1.14.
When is next earnings date of Nabriva Therapeutics PLC(STU:NTY)?
The next earnings date of Nabriva Therapeutics PLC(STU:NTY) is 2024-05-22 Est..
Does Nabriva Therapeutics PLC(STU:NTY) pay dividends? If so, how much?
Nabriva Therapeutics PLC(STU:NTY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers